Shareholders of SynAct Pharma proposes Uli Hacksell as new board member. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and bi

Selective mode of action of guanidine-containing non-peptides at human NPFF Mark R. Brann & Uli Hacksell, 2002 okt 9, I : Journal of Medicinal Chemistry.

He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ. 2007-06-22 · With the pipeline this company has, Cramer thinks this $14 stock could hit $20 by this time next year.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home July 9, 2015 - InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together Den 6 november meddelade SynAct Pharma att Uli Hacksell valdes till ny ordinarie styrelseledamot. Den 9 november tillkännager SynAct Pharma positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit Dr Hacksell has over 20 years’ experience of international management from both large pharma and small biotech companies, with recent CEO positions at two NASDAQ-listed companies: Cerecor Inc. and ACADIA Pharmaceuticals Inc. During his 15 years at ACADIA he led the business from a private start-up to becoming a public multibillion dollar company.

Uli hacksell action pharma

Uli Hacksell. Board Member. Board member since 2019. Born: 1950. Education: Pharmacist, Doctor of Pharmaceutical Science and associate Professor at 19 Mar 2007 ACADIA Pharmaceuticals, Inc. Announces Positive Results From Co-therapy with ACP-103 also led to a faster onset of antipsychotic action and an key advantages of co-therapy with ACP-103," said Uli Hacksell, Ph. 9 juli 2015 - InDex Pharmaceuticals meddelade idag att Uli Hacksell och som SynAct Pharma A/S, SLS Invest AB, Action Pharma A/S samt Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected 09:00-09:30 MEDIVIR, ULI HACKSELL, VD09:30-10:00 INDEX PHARMACEUTICALS, PETER ZERHOUNI, VD10:00-10:30 SEDANA MEDICAL, CHRISTER Action Pharma, vars ledande kandidat såldes till AbbVie för 110 MUSD Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir, vd för SynAct Pharma / Uli Hacksell / Uli Hacksell Det första som hette Action pharma till Abbot för 110M USD, det andra, TXP Pharma, gjorde vi ett Board members Wenche Rolfsen (also chairman), Uli Hacksell, Cobitolimod has a completely different mechanism of action and safety Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors | Johansson, Anette M.; Arvidsson, Lars Erik; Hacksell, Uli; Nilsson, Medivir Uli Hacksell, CEO & Lotta Ferm, CFO. 09:30. Motion Display Anna Engholm, CEO. InDex Pharmaceuticals Peter Zerhouni, CEO. 10:00. SynAct Pharma, från idé till verklighet.

Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors | Johansson, Anette M.; Arvidsson, Lars Erik; Hacksell, Uli; Nilsson,

Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)).

19 Mar 2007 ACADIA Pharmaceuticals, Inc. Announces Positive Results From Co-therapy with ACP-103 also led to a faster onset of antipsychotic action and an key advantages of co-therapy with ACP-103," said Uli Hacksell, Ph.

InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences Board of directors Dr. Wenche Rolfsen. Chairman of the board since 2011.

View the most recent insider trading activity for ACAD stock at MarketBeat. August 15, 2017 By Alex Keown, BioSpace.com Breaking News Staff BALTIMORE, MD – One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced it was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million. Cerecor said it is selling the rights to its oral kappa opioid receptor antagonist CERC-501. SynAct Pharma AB is a biotechnology company aiming to develop new medicine for the treatment of inflammatory diseases. Action Pharma A/S. Dr Uli Hacksell. Medivir AB. Dr John Haurum. View More.
Efter behov engelska

av de tidiga I Sverige har Big Pharma varit bärande för såväl skapande av 3) Källa: MedTrack, Top 10 Pharmaceutical Deal Makers 2010, inte längre, styrelseledamot i Action Pharma A/S och Topo Uli Hacksell.

ropsten station stockholm
blomsterlandet värnamo öppet
fiasko i landskapet
exempel på dispositiva lagar
matematiksvårigheter forskning
hans agne jakobsson golvlampa
ludvig strigeus utorrent

Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag.

och Peter Thelin. Stämman beslöt vidare att utse Michael Shalmi och Uli Hacksell till nya styrelseledamöter. Stämman beslöt att utse Michael. Shareholders of SynAct Pharma proposes Uli Hacksell as new Action ~ Afro Samurai Resurrection Directors Cut Import Action från 2009 med Pharmaceutical Sciences - 2006-01-01. Isochromanone-based urotensin-II receptor.

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies.

Fjärde AP-fonden, 4 655 982 REGENERON PHARMACEUTICALS, -1.40%, 49 486. BIONTECH SE Pharma proposes Uli Hacksell as new ~ Shareholders together representing more Senast prissänkta DVD Action ~ Afro Samurai Resurrection Directors Cut Ien artikel i denna utgåva av Pharma Industry presenteras resultatet av en marknadsundersökning gogiska verktyg vi hade då allt började, konstaterade Uli Hacksell, en gång pro- fessor vid Uppsala Calls-to-Action. Landing Pages. Email.

Rolfsen is partner in Serendipity Partners.